Your fact-checks will appear here
American pharmaceutical company
The American Heart Association (AHA) regularly discloses a multi-year roster of corporate donors that includes numerous pharmaceutical, biotech and medical-device firms; its published “pharma funding”...
The MHRA’s April 30, 2025 announcement authorised a subcutaneous (under‑the‑skin) formulation of nivolumab for use across a broad range of solid‑tumour indications and stated the approval covers 15 ca...
The American Heart Association (AHA) publishes year-by-year disclosures listing pharmaceutical, biotech and device-company support, and those disclosures show a recurring set of large donors across th...
Nine major drugmakers — Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche’s U.S. unit), Gilead Sciences, GSK (including ViiV), Merck, Novartis and Sanofi — agreed to sell selected me...
The NHS has begun rolling out an under‑the‑skin injectable form of the immunotherapy drug nivolumab (Opdivo) that regulators have approved as an alternative to the intravenous infusion, and NHS Englan...
Yes — nine major pharmaceutical companies publicly agreed to lower the price of some of their medicines in deals announced by the Trump administration on Dec. 19, 2025, committing to “most-favored-nat...
Large, randomized anti‑tau antibody trials enrolling people with mild cognitive impairment (MCI) are actively underway and have staggered completion dates through 2027–2028, while the reporting provid...
Pharmaceutical companies have sharply increased investment in oncology across R&D, licensing deals, M&A and manufacturing capacity, driven by a deep clinical pipeline, rising patient prevalence and th...